US Earnings Financial Results SEC Filings — June 10, 2026

10-06-2026

Vanguard Green Investment Ltd reported zero revenue for the three and nine months ended April 30, 2026, with net losses widening to $19,062 (Q3) and $66,191 (nine months) compared to $11,146 and $40,251 in the prior-year periods. The company's accumulated deficit increased to $2,627,012 and total stockholders' deficit deepened to $790,769, while cash and cash equivalents fell to just $55 from $93 at July 31, 2025. The company continues to rely on director loans ($57,749 in financing during the nine months) to fund operations, with no revenue-generating activities reported.

• · Revenue remained zero for all periods reported, with no cost of revenue or gross profit.
• · Other income was $0 for the three and nine months ended April 30, 2026, compared to $832 and $875 in the prior-year periods.
• · Selling and marketing expenses were $0 for all periods.
• · Income tax provision was $0 for all periods.
• · No foreign currency translation loss was recorded.
• · Net loss per share (basic and diluted) was $(0.0003) for Q3 2026 vs $(0.0002) for Q3 2025, and $(0.0011) vs $(0.0007) for the nine-month periods.
• · Weighted average shares outstanding remained constant at 59,434,838.
• · Property, plant and equipment was fully depreciated and impaired to $0 as of both balance sheet dates.
• · Patent and trademark intangible asset was $0.
• · Total assets increased slightly from $15,258 to $16,555, driven by a rise in prepayments.
• · Total liabilities increased from $739,836 to $807,324, primarily due to higher director and third-party loans.
• · The company had no preferred stock issued or outstanding.
• · Cash used in operating activities increased to $57,787 from $43,981 (nine months).
• · The company's only source of cash from financing was director loans.
• · The company's cash balance at period end was only $55, indicating severe liquidity constraints.

10-06-2026

Core & Main, Inc. reported net sales of $1,910M for Q1 FY26 (ended May 3, 2026), essentially flat versus $1,911M in Q1 FY25. Net income attributable to Core & Main increased 8.0% to $108M from $100M, driven by a 2.0% improvement in gross profit to $520M and lower interest expense. However, sales in the pipes, valves & fittings category declined 1.8% to $1,274M, and storm drainage sales fell 5.8% to $278M, partially offset by growth in fire protection (+17.1%) and smart utility products (+7.8%). Cash and cash equivalents decreased sharply to $150M from $220M at the start of the period, primarily due to $88M in share repurchases and $42M in tax receivable agreement payments.

• · Net cash provided by operating activities was $82M in Q1 FY26, up from $77M in Q1 FY25.
• · Capital expenditures were $14M in Q1 FY26, compared to $13M in the prior-year period.
• · Total assets increased to $6,324M as of May 3, 2026 from $6,085M as of February 1, 2026.
• · Long-term debt remained relatively stable at $2,120M (May 3, 2026) vs $2,124M (Feb 1, 2026).
• · The company repurchased 1,773,703 Class A shares in Q1 FY26 for $88M, compared to 837,268 shares for $39M in Q1 FY25.
• · Interest expense decreased to $27M in Q1 FY26 from $30M in Q1 FY25.
• · Provision for income taxes was $37M in Q1 FY26, up from $36M in Q1 FY25.

10-06-2026

Chewy reported net income of $94.8M for the 13 weeks ended May 3, 2026, up 51.9% from $62.4M in the prior-year period, driven by net sales growth of 7.7% to $3,357.2M. However, operating cash flow remained weak at $108.5M (though up from $86.4M), and the company's cash position dropped sharply to $485.2M from $860.1M at the start of the period, largely due to $200.0M in stock repurchases and $174.8M in acquisition spending. Gross profit margin improved to 30.1% from 29.6%, but selling, general and administrative expenses rose as a percentage of sales.

• · SG&A expense increased to $676.8M from $653.1M YoY, representing 20.2% of net sales vs 21.0%.
• · Advertising and marketing expense rose to $206.1M from $193.8M YoY, representing 6.1% of net sales vs 6.2%.
• · Interest income net decreased to $2.8M from $3.2M YoY due to lower cash balances.
• · Goodwill increased to $113.2M from $39.4M, reflecting an acquisition during the period.
• · Inventory increased to $1,007.9M from $864.8M, a 16.5% rise.
• · Trade accounts payable increased to $1,311.1M from $1,221.4M.
• · Net cash used in financing activities was $254.8M, driven by $200.0M in stock repurchases and $53.3M in tax withholdings.
• · Cash paid for acquisition of business was $174.8M.

10-06-2026

SailPoint, Inc. reported Q1 FY26 revenue of $280.1M, up 21.6% YoY from $230.5M, driven by strong subscription growth (+23.5% to $265.8M). Net loss narrowed significantly to $74.7M from $187.3M in the prior year period, reflecting improved operating leverage. However, services and other revenue declined 5.4% YoY to $14.3M, and the company's accumulated deficit widened to $325.5M from $250.8M at year-end.

• · SaaS revenue grew 35.4% YoY to $178.5M, while maintenance and support declined 7.6% to $34.6M.
• · Gross profit margin improved to 64.6% in Q1 FY26 from 55.4% in Q1 FY25.
• · Operating expenses decreased 16.5% YoY to $260.9M, with G&A down 44.4% and sales & marketing down 6.3%.
• · Net cash provided by operating activities was $38.2M in Q1 FY26 vs. $(96.8)M used in Q1 FY25.
• · Equity-based compensation expense was $70.6M in Q1 FY26, down from $105.7M in Q1 FY25.
• · Deferred revenue decreased to $535.3M (current + non-current) from $555.2M at year-end.
• · Goodwill remained unchanged at $5.15B, and intangible assets net decreased to $1.33B from $1.38B.
• · No IPO proceeds or debt repayments occurred in Q1 FY26, compared to $1.26B in IPO proceeds and $1.04B in term loan repayments in Q1 FY25.
• · Net loss per share improved to $(0.13) from $(0.42) in the prior year period.

10-06-2026

Bark, Inc. filed its 10-K for the fiscal year ended March 31, 2026, reporting total revenue of $394.8M, down 18.5% from $484.2M in FY2025, driven by a 21.9% decline in Direct-to-Consumer (DTC) revenue to $324.9M. The company narrowed its net loss to $39.0M from $32.9M in the prior year, a 18.6% increase in net loss, while gross margin improved to 61.3% from 62.4%. Total orders fell 23.8% to 10.06 million from 13.21 million, though average order value remained nearly flat at $31.06.

• · DTC gross margin improved to 68.4% in FY2026 from 66.1% in FY2025.
• · Commerce gross profit declined 9.7% YoY to $28.1M.
• · Shipping and fulfillment expense decreased 14.1% YoY to $119.4M.
• · Advertising and marketing as a percentage of revenue fell to 15.0% from 17.3%.
• · General and administrative expense as a percentage of revenue increased to 56.4% from 52.3%.
• · Interest income dropped 61.8% YoY to $1.9M.
• · Interest expense decreased 33.4% YoY to $1.9M.
• · Other income, net surged 768.2% YoY to $1.1M.
• · Commerce revenue grew 2.3% YoY, partially offsetting DTC decline.
• · Total orders fell 23.8% YoY, while average order value remained essentially flat at $31.06.

10-06-2026

Aethlon Medical Inc. (AEMD) filed its 10-K annual report for fiscal year ended March 31, 2026. The company continues to develop its Hemopurifier for advanced/metastatic cancer and life-threatening viruses, but remains pre-revenue with a net loss of $7.15 million in FY2026, an improvement from a $13.40 million loss in FY2025. Cash flow from operations was negative at -$6,998,000, and total cash decreased by $474,000 year-over-year, with only $1,570,449 common shares outstanding as of March 31, 2026.

• · The company's cash balance decreased by $474,000 in FY2026, compared to an increase of $69,000 in FY2025.
• · Investing activities consumed only $4,000 in FY2026 vs. $0 in FY2025.
• · Effect of exchange rate on cash was a positive $7,000 vs. negative $12,000 in the prior year.
• · PEO 2 total compensation rose to $826,922 in FY2026 from $500,000 in FY2025, an increase of 65.4%.
• · Average non-PEO NEO compensation was $402,365 in FY2026, down 8.1% from $437,844 in FY2025.
• · TSR collapsed from $9.36 per $100 invested in FY2025 to $0.72 in FY2026, a decline of 92.3%.
• · The company maintains a going concern risk given continued operating losses and reliance on financing activities for cash.
• · Principal accountant Haskell & White, LLP provided audit services for FY2026 and FY2025.
• · Risk factors include failure to raise additional funds, Nasdaq listing non-compliance, and clinical trial uncertainties.
• · A $100 investment at the start of FY2024 would be worth only $0.72 by end of FY2026, a cumulative decline of 99.3%.

10-06-2026

SMITH MIDLAND CORP reported a mixed first quarter for fiscal 2026. While total revenue declined 5% year-over-year to $21.6M (from $22.7M) due to a significant drop in barrier rentals, product sales grew 29% and shipping and installation revenue rose 58%. Net income slumped 60% to $1.3M from $3.3M, reflecting a lower gross margin. Cash from operations improved to $3.1M from $2.2M, and total assets increased to $92.2M.

• · Basic EPS fell to $0.25 from $0.63, diluted EPS to $0.25 from $0.62.
• · Cost of sales increased to $17.3M from $15.7M, while gross profit dropped to $4.3M from $7.0M (gross margin declined from 30.7% to 19.9%).
• · Cash and cash equivalents rose to $13.2M from $11.9M at year-end 2025.
• · Accounts payable - trade jumped to $8.3M from $5.5M, while deferred revenue (current) decreased to $0.9M from $1.1M.
• · Capital expenditures nearly tripled to $1.6M from $0.6M in the prior-year quarter.
• · Non-cash investing activity: capital expenditures in accounts payable were $0.9M.
• · Unbilled trade receivables (contract assets) rose to $1.8M from $1.2M at year-end 2025.
• · Allowance for expected credit losses increased to $651,000 from $539,000.

10-06-2026

RemSleep Holdings Inc. (RMSL) reported no revenue for Q1 2026, consistent with the prior-year period. Net loss widened significantly to $289,924 from $85,488 in Q1 2025, driven by a 76% increase in operating expenses to $231,348. Cash fell 59% to $87,953 from $214,514 at year-end 2025, and stockholders' equity turned negative at ($122,551) versus $32,062 at December 31, 2025, reflecting ongoing cash burn and operating losses.

• · Inventory increased 52% to $70,356 from $46,304 at year-end 2025.
• · Accounts payable rose 51% to $173,357 from $114,761.
• · The company issued 35,419,997 shares of common stock for note payable principal and accrued interest, valued at $135,311.
• · Derivative liability increased to $78,038 from $63,920 at December 31, 2025.
• · Accumulated deficit grew to $18,580,980 from $18,291,056.

10-06-2026

Anixa Biosciences Inc. reported total assets of $14,865 (USD) as of April 30, 2026, down from $16,080 as of October 31, 2025 (-7.6%). Cash and cash equivalents increased to $1,477 from $1,244 (+18.7%) while short-term investments decreased to $12,209 from $13,930 (-12.4%). For the three months ended April 30, 2026, total operating expenses were $2,647 vs $3,003 in the comparable 2025 quarter (a 11.9% decrease) and net loss improved to $(2,536) from $(2,813) (a 9.8% improvement); however, six-month results show total operating expenses of $5,363 in 2026 vs $6,389 in 2025 (a 16.1% decrease) and net loss of $(5,121) vs $(6,026) (a 15.0% improvement), indicating reduced spending and smaller losses but continued negative earnings and an accumulated deficit of $(256,758).

• · Revenue: $- for all reported periods (no revenue recognized).
• · Accumulated deficit increased to $(256,758) as of April 30, 2026 from $(251,677) as of October 31, 2025 (a $5,081 increase in deficit over six months, consistent with six-month net loss).
• · Net cash used in operating activities for the six months ended April 30, 2026 was $(4,351) compared with $(4,407) for the six months ended April 30, 2025 (slight improvement).
• · Proceeds from maturities of short-term investments were $26,292 for the six months ended April 30, 2026 while disbursements to acquire short-term investments were $(24,642), producing net investing inflow of $1,650.
• · Net cash provided by financing activities was $2,934 for the six months ended April 30, 2026 vs $1 for the six months ended April 30, 2025, driven primarily by at-the-market offering proceeds of $2,870 (net).
• · Non-cash stock-based compensation (R&D + G&A) for the three months ended April 30, 2026 totaled $665 ($286 R&D + $379 G&A) and for the three months ended April 30, 2025 totaled $988 ($417 R&D + $571 G&A).

10-06-2026

J.Jill, Inc. reported a challenging first quarter for fiscal 2026, with net sales declining 6.0% year-over-year to $144.4 million from $153.6 million. Both retail and direct channels experienced declines, with retail sales down 4.0% and direct sales down 8.3%. Net income fell sharply by 59.9% to $4.7 million from $11.7 million, and diluted earnings per share dropped to $0.31 from $0.76. However, the company maintained a healthy gross margin of 68.3%, reduced selling, general and administrative expenses by 1.5%, and lowered interest expense by 32.9% due to debt reduction.

• · Gross profit margin declined to 68.3% from 71.8% in the prior year period.
• · Selling, general and administrative expenses decreased 1.5% year-over-year to $89.7 million.
• · Interest expense decreased 32.9% to $1.9 million due to lower debt levels.
• · Net cash provided by operating activities fell 68.4% to $1.7 million from $5.3 million.
• · The company repurchased 68,500 shares of treasury stock for $0.8 million during the quarter.
• · Cash dividends declared increased to $0.09 per share from $0.08 per share in the prior year period.
• · Total debt (current portion of long-term debt plus long-term debt) was $72.9 million as of May 2, 2026, down from $73.3 million as of January 31, 2026.
• · Inventories decreased 8.8% to $63.9 million from $70.1 million at year-end.
• · Accounts payable decreased 23.5% to $44.1 million from $57.7 million at year-end.
• · The company had $36.3 million in cash and cash equivalents and $71.3 million in long-term debt as of May 2, 2026.

10-06-2026

Arax Holdings Corp (ARAT) filed its audited 10-K for the fiscal year ended October 31, 2024, reporting a net loss of $3.56M, a significant improvement from the $6.59M net loss in the prior year. Revenue declined 32.4% to $613,636 (including $301,750 from a related party), while total assets fell 58.3% to $902,220 and stockholders' equity turned negative to ($521,414) from positive $1.81M. The company also restated its prior year financials, reducing previously reported total assets by $4.98M and eliminating a prior $18.55M impairment charge.

• · The company restated its FY2023 financials, reducing total assets by $4.98M (from $7.15M to $2.17M), eliminating a prior $18.55M impairment charge, and reclassifying $4.76M in software development costs.
• · Accounts receivable of $301,750 were recognized in FY2024, compared to $0 in the prior restated year.
• · Notes payable of $765,000 were recorded in FY2024, up from $0 in FY2023.
• · Stock-based compensation decreased 63.1% to $724,862 in FY2024 from $1,963,296 in FY2023.
• · The company reported a $169,373 impairment expense and a $103,400 loss on short-term borrowing settlement in FY2024.
• · Weighted average shares outstanding increased 88.6% to 127.8 million in FY2024 from 67.8 million in FY2023.
• · The company has limited international operations in South Africa and Switzerland (Cilandro SA) and does not hedge foreign currency exposure.
• · Total stockholders' equity turned negative to ($521,414) as of October 31, 2024, compared to positive $1.81M a year earlier.

10-06-2026

Future Money Acquisition Corp (FMAC) completed its IPO during the six months ended April 30, 2026, raising $112 million from the public offering and $3.04 million from private placements. The company reported net income of $243,936 for the six-month period, driven by $347,509 in interest income from the Trust Account, but incurred a net loss of $46,172 in the first quarter before turning profitable in the second quarter. Despite the overall profit, the company recorded a net loss of $3.48 million attributable to non-redeemable shareholders for the six-month period, indicating that profitability is heavily dependent on trust account earnings and that operating costs continue to exceed operating income.

• · Total operating loss (formation and general costs) was $103,573 for the six months ended April 30, 2026, compared to $24,487 for the period from inception (September 29, 2025) through October 31, 2025.
• · Net cash used in operating activities was $183,692 for the six months ended April 30, 2026.
• · Proceeds deposited in Trust Account (investing activities) totaled $112,560,000 for the six-month period.
• · The company had 4,694,069 ordinary shares issued and outstanding as of April 30, 2026, up from 4,362,069 as of October 31, 2025.
• · Total shareholders’ equity improved from a deficit of $24,487 at October 31, 2025 to $510,387 at April 30, 2026.
• · Non-cash accretion of redeemable ordinary shares to redemption value was $5,417,265 for both the three and six months ended April 30, 2026.

10-06-2026

Academy Sports & Outdoors reported net sales of $1.44B for the 13 weeks ended May 2, 2026, up 6.7% YoY from $1.35B, driven by growth across all merchandise divisions. Net income rose 14.4% to $52.7M from $46.1M, with diluted EPS increasing to $0.80 from $0.68. However, the company continued aggressive share repurchases (1.7M shares for $99.3M) and saw a significant cash outflow from inventory build of $150.7M, while operating cash flow improved modestly to $160.6M.

• · Merchandise inventories increased by $150.7M during the quarter, a significant cash outflow.
• · Accounts payable increased by $178.0M, partially offsetting the inventory build.
• · Total debt remained stable at $485M, with no borrowings under the ABL Facility.
• · Right-of-use assets obtained in exchange for new operating leases totaled $92.7M, up from $77.4M in the prior year.
• · Non-cash capital expenditures were $20.9M, indicating additional capital commitments not yet reflected in cash flow.
• · Gift card liability decreased to $88.6M from $99.6M at the beginning of the quarter, driven by redemptions exceeding issuances.
• · The company paid $3.1M in interest and $0.1M in income taxes during the quarter.

10-06-2026

YAN CHUANG GROUP INC. reported zero revenue for the three and nine months ended March 31, 2026 and 2025, with a net loss of $8,051 for the quarter and $19,521 for the nine-month period. Cash and cash equivalents declined sharply from $37,333 at June 30, 2025 to $22,833 at March 31, 2026, driven by operating cash outflows of $14,500. The company's accumulated deficit grew to $48,288, and total stockholders' equity fell from $21,233 to $4,233, reflecting ongoing losses with no revenue generation.

• · The company was incorporated on June 4, 2025, and had no operations in the prior comparable periods (three and nine months ended March 31, 2025).
• · General and administrative expenses were $8,051 for the quarter and $19,521 for the nine-month period, with no prior period expenses.
• · Additional paid-in capital increased from $40,000 at June 30, 2025 to $42,521 at March 31, 2026, reflecting capital contributions of $2,521 over the nine months.
• · Accrued expenses rose from $16,100 at June 30, 2025 to $18,600 at March 31, 2026.
• · The company is a non-accelerated filer, an emerging growth company, and a smaller reporting company.

10-06-2026

Citi Trends Inc reported net income of $7.754M for the thirteen weeks ended May 2, 2026, a dramatic increase from $0.871M in the same period last year, driven by a 14.4% YoY rise in net sales to $230.858M. However, selling, general and administrative expenses also rose 6.5% YoY to $79.745M, and inventory increased slightly by 1.5% from the prior quarter-end, indicating persistent cost pressures.

• · No stock repurchases during the quarter vs. $6.315M in repurchases in the prior-year period.
• · Cash provided by operating activities was $20.875M, compared to cash used of $10.969M in the prior-year period.
• · Capital expenditures increased to $5.833M from $2.104M in the prior-year period.
• · Basic earnings per share rose to $0.95 from $0.11; diluted EPS rose to $0.91 from $0.11.
• · Weighted average diluted shares outstanding increased to 8,484,075 from 8,170,456.
• · Store rent expense increased to $17.701M from $16.327M, a YoY increase of 8.4%.